Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
- PMID: 29765563
- PMCID: PMC5940404
- DOI: 10.18632/oncotarget.25085
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
Abstract
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.
Keywords: bibliometric analysis; clinical trials; pancreatic cancer.
Conflict of interest statement
CONFLICTS OF INTEREST AVB is in receipt of grants, honoraria and/or advisory board fees from MRC, Wellcome Trust, Cancer Research UK, Pancreatic Cancer UK, Chief Scientists Office of the Scottish Government, Pancreatic Cancer Action Network, Celgene, Clovis Oncology, Cure Forward, AstraZeneca, Elstar Therapeutics, Sagely Health and Abcodia. The other authors have no disclosure or conflicts of interest to declare.
Figures



References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. - PubMed
-
- Sheahan AV, Phillips PA, Khachigian LM. Therapeutic perspectives on pancreatic cancer. Curr Cancer Drug Targets. 2013;13:400–10. - PubMed
-
- Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, et al. Groupe Tumeurs Digestives of Unicancer, and PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous